Sinclair Pharma Share Discussion Threads

[red ninja] 27/2/2012 20:54

David

Can't make it to London on that date, but thanks for you invitation.

If you add a few words on the presentation I'd be grateful.

RN

[davidosh] 27/2/2012 17:40

The chart looks horrible but hopefully the recent results can be a turning point. I do not hold any but willing to be convinced that this is now a good point to make a maiden purchase.

Anyway to help to get an understanding of the company Sinclair are one of the four companies that have agreed to present to investors at our Mello Central event this coming Thursday in London at the FinnCap HQ next to Liverpool Street station starting at 5.30pm (Drinks from 5pm and a buffet meal after the presentations at 8pm)

All the Hospitality is free and I have over 50 investors attending these events on a regular basis so you are very welcome to join us.

You can email me to request a place by sending an email with 'meeting' in the Subject Line to [e-mail] (a spam filter will discard emails without the word 'meeting').

[red ninja] 23/2/2012 20:25

Sharecast :

Skin treatments supplier Sinclair IS Pharma is growing the top line rapidly after a rash of acquisitions but the bottom line remains a blemish as it beds things down following its merger with IS Pharma. Revenues in the second half of 2011 rose 67% to £23.4m from £14.1m in the corresponding period of 2010, with like-for-like revenues up 9%. Ignoring exceptional items, the company's earnings before interest, tax, depreciation and amortisation (EBITDA) were positive, at £0.7m versus a loss of £1.3m the year before, but the company still registered a loss per share of 1.4p, compared to a loss of 1.9p at the interim stage last year. The loss came about because the company saw a one-off £2.2m hit for administrative expenses relating to the merger. Loss before tax widened to £5.56m from £4.02m the year before, but excluding exceptional items it narrowed to £2.91m from £3.52m

[red ninja] 23/2/2012 09:57

Mmm seems to me we are heading in the right direction, but it is more of a medium term stock.

Topped up with a few at 22p.

[clogue] 23/2/2012 08:40

Sorry RN just spotted your last post.
These have simply drifted down and I was not paying attention. Massive restructuring and activity and I can only hope they know what they are doing.

dealit: the results look fine and having stuck with them during all the upheaval I am inclined to just wait a bit longer.
For a newcomer this would be a very good entry point as I think all the deals could kick in soon and they do have some very good and comparatively low risk products.

Happy to hold. Well perhaps not happy but certainly willing to hold as I consider that there is real upside with little real risk.

[dealit] 23/2/2012 08:01

At a quick glance not a bad set of results IMHO>

[red ninja] 27/1/2012 15:59

Am I the last holder, I am thinking of a top up at 20p.

[philo124] 24/1/2012 12:30

I have finally given up on this Dog.

[dealit] 13/1/2012 07:25

The poitive news as arrived today PSH seem to be on the up IMHO.

[dealit] 06/1/2012 07:34

I notice that a director bought 750,000 on the 3rd Jan. Last year their was a trading statement on the 11th, Director buying of late makes me feel that their is some positive news shortly.

[dealit] 22/12/2011 07:20

Yes PHILO, another buy 21-Dec-11 £11,000.00 Robert Stuart Swanson 50,000 @ 22.00p I do feel that the share price will move north in 2012. 4 Brokers say strong buy, time to increase my holding DYOR.

[philo124] 17/12/2011 21:58

That's a tidy sum!

[dealit] 17/12/2011 21:32

Director buying:

15 December 2011, Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS"), the international specialty pharma company, was informed today that Stuart Swanson, Non-Executive Director, has recently acquired ordinary shares of 1p each ("Ordinary Shares") in the Company as follows:



9 December 2011 318,000 Ordinary shares at 23.23p

12 December 2011 72,000 Ordinary shares at 23.5p

13 December 2011 243,538 Ordinary shares at 23.5p

14 December 2011 146,283 Ordinary Shares at 23.46p

[red ninja] 09/12/2011 23:20

Sinclair IS Pharma (SPH) kept its "buy" rating from Singer Capital, with a 48p target price. The broker expects the medical group's acquisition of dermatological specialist ABT's non-US assets for 21 million pounds to be earning enhancing in its first full year and to increase its distribution rights for scar therapy Kelo-cote. With a strong core in France, Italian and Germany, Singer believes the addition will strengthen its presence in Latin America and Asia, as well as reduce existing sales costs. Sinclair shares gained 0.5p to 23.5p.

[connello] 28/11/2011 18:58

1 million stock changed hands today..... was it a rollover?

[red ninja] 16/11/2011 15:47

It seems to me we've seen a couple of director buys, the last one at around £75k. Hopefully this is a good indication that better days are ahead.

[philo124] 16/11/2011 13:54

I think that's what we are all looking forward to.

[clogue] 16/11/2011 13:52

For a "non core" asset this was a pretty good looking price,£3m turnover brings in £11.1m.
This puts a value of £120m on the latest turnover figure of £33m, as of 30th June 2011.
Given the market cap. is £58m I would suggest that there is some upside available here.
The company said that it was generating sufficient cash to remove the need for fundraising and this £11m obviously puts things absolutely beyond doubt.
Restructuring, one off costs, have been substantial and have had an obvious pull on the share price but a return to profit this year would have a dramatic effect on the price.

[danielmiller1] 15/11/2011 09:56

Could be but you dont sell the family silver....or do you?

[philo124] 15/11/2011 09:54

The full RNS on balance was very good imo.

[danielmiller1] 15/11/2011 09:39

Looks like they were short of cash as this product was selling well, with great long term profit potential!

[red ninja] 04/11/2011 15:31

4 November 2011, Sinclair IS Pharma plc (AIM:SPH.L), the international specialty pharma company, was informed today that Stuart Swanson, Non-Executive Director, has recently acquired ordinary shares of 1p each ("Ordinary Shares") in the Company as follows:

22 September 2011 100,000 ordinary shares at 25p
23 September 2011 25,000 Ordinary Shares at 25p
26 September 2011 78,210 Ordinary Shares at 25p
27 September 2011 85,496 Ordinary Shares at 25p
28 September 2011 11,294 Ordinary Shares at 25p
25 October 2011 7,286 Ordinary Shares at 25p

Following these purchases, Mr Swanson is interested in 1,307,286 Ordinary Shares, 0.34% per cent. of the issued share capital of the Company.